We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00787254
First Posted: November 7, 2008
Last Update Posted: February 3, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Takeda
Results First Submitted: February 3, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Stomach Ulcer
Duodenal Ulcer
Interventions: Drug: Lansoprazole
Drug: Gefarnate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled at sites in Japan from April 2007 to May 2009.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants were enrolled in either lansoprazole, once daily (QD) or gefarnate, twice daily (BID) treatment groups. NSAID = Nonsteroidal anti-inflammatory drug.

Reporting Groups
  Description
Lansoprazole 15 mg QD Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
Gefarnate 50 mg BID Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.

Participant Flow:   Overall Study
    Lansoprazole 15 mg QD   Gefarnate 50 mg BID
STARTED   185   181 
COMPLETED   109   99 
NOT COMPLETED   76   82 
Adverse Event                24                23 
Protocol Violation                26                23 
Withdrawal by Subject                16                11 
Lack of Efficacy                4                15 
NSAIDs discontinuation                1                2 
Institution closed                1                0 
Physician Decision                4                8 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Lansoprazole 15 mg QD Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
Gefarnate 50 mg BID Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
Total Total of all reporting groups

Baseline Measures
   Lansoprazole 15 mg QD   Gefarnate 50 mg BID   Total 
Overall Participants Analyzed 
[Units: Participants]
 185   181   366 
Age, Customized 
[Units: Participants]
     
≤39 years   7   6   13 
Between 40 and 49 years   18   13   31 
Between 50 and 59 years   38   43   81 
Between 60 and 64 years   33   29   62 
Between 65 and 69 years   33   30   63 
Between 70 and 79 years   43   48   91 
≤80 years   13   12   25 
Gender 
[Units: Participants]
     
Female   112   107   219 
Male   73   74   147 
Region of Enrollment 
[Units: Participants]
     
Japan   185   181   366 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Gastric Ulcer and/or Duodenal Ulcer   [ Time Frame: 24 Months ]

2.  Secondary:   Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)   [ Time Frame: Baseline and Month 3. ]

3.  Secondary:   Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)   [ Time Frame: Baseline and Month 6. ]

4.  Secondary:   Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)   [ Time Frame: Baseline and Month 12. ]

5.  Secondary:   Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)   [ Time Frame: Baseline and Month 18. ]

6.  Secondary:   Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 24)   [ Time Frame: Baseline and Month 24. ]

7.  Secondary:   Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)   [ Time Frame: Baseline and Month 3. ]

8.  Secondary:   Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)   [ Time Frame: Baseline and Month 6. ]

9.  Secondary:   Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)   [ Time Frame: Baseline and Month 12. ]

10.  Secondary:   Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)   [ Time Frame: Baseline and Month 18. ]

11.  Secondary:   Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 24)   [ Time Frame: Baseline and Month 24. ]

12.  Secondary:   Number of Participants With Gastric or Duodenal Ulcer or Gastric or Duodenal Hemorrhagic Lesion (Upper Gastrointestinal Hemorrhage)   [ Time Frame: On occurrence (up to month 24). ]

13.  Secondary:   Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 3)   [ Time Frame: Baseline and Month 3. ]

14.  Secondary:   Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 6)   [ Time Frame: Baseline and Month 6. ]

15.  Secondary:   Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 12)   [ Time Frame: Baseline and Month 12. ]

16.  Secondary:   Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 18)   [ Time Frame: Baseline and Month 18. ]

17.  Secondary:   Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 24)   [ Time Frame: Baseline and Month 24. ]

18.  Secondary:   Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 3)   [ Time Frame: Baseline and Month 3. ]

19.  Secondary:   Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 6)   [ Time Frame: Baseline and Month 6. ]

20.  Secondary:   Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 12)   [ Time Frame: Baseline and Month 12. ]

21.  Secondary:   Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 18)   [ Time Frame: Baseline and Month 18. ]

22.  Secondary:   Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 24)   [ Time Frame: Baseline and Month 24. ]

23.  Secondary:   Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 3)   [ Time Frame: Baseline and Month 3. ]

24.  Secondary:   Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 6)   [ Time Frame: Baseline and Month 6. ]

25.  Secondary:   Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 12)   [ Time Frame: Baseline and Month 12. ]

26.  Secondary:   Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 18)   [ Time Frame: Baseline and Month 18. ]

27.  Secondary:   Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 24)   [ Time Frame: Baseline and Month 24. ]

28.  Secondary:   Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 3)   [ Time Frame: Baseline and Month 3. ]

29.  Secondary:   Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 6)   [ Time Frame: Baseline and Month 6. ]

30.  Secondary:   Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 12)   [ Time Frame: Baseline and Month 12. ]

31.  Secondary:   Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 18)   [ Time Frame: Baseline and Month 18. ]

32.  Secondary:   Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 24)   [ Time Frame: Baseline and Month 24. ]

33.  Secondary:   Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 3)   [ Time Frame: Baseline and Month 3. ]

34.  Secondary:   Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 6)   [ Time Frame: Baseline and Month 6. ]

35.  Secondary:   Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 12)   [ Time Frame: Baseline and Month 12. ]

36.  Secondary:   Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 18)   [ Time Frame: Baseline and Month 18. ]

37.  Secondary:   Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 24)   [ Time Frame: Baseline and Month 24. ]

38.  Secondary:   Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 3)   [ Time Frame: Baseline and Month 3. ]

39.  Secondary:   Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 6)   [ Time Frame: Baseline and Month 6. ]

40.  Secondary:   Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 12)   [ Time Frame: Baseline and Month 12. ]

41.  Secondary:   Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 18)   [ Time Frame: Baseline and Month 18. ]

42.  Secondary:   Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 24)   [ Time Frame: Baseline and Month 24. ]

43.  Secondary:   Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 3)   [ Time Frame: Baseline and Month 3. ]

44.  Secondary:   Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 6)   [ Time Frame: Baseline and Month 6. ]

45.  Secondary:   Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 12)   [ Time Frame: Baseline and Month 12. ]

46.  Secondary:   Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 18)   [ Time Frame: Baseline and Month 18. ]

47.  Secondary:   Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 24)   [ Time Frame: Baseline and Month 24. ]

48.  Secondary:   Number of Participants With Adverse Events   [ Time Frame: Per Incidence (up to 24 months). ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
This study was prematurely discontinued due to results available from a parallel study (AG-1749-CCT-351; NCT00762359) demonstrating a preventive effect on ulcer occurrence which impacted the risk/benefit profile.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Sr. VP Clinical Science
Organization: Takeda Global Research and Development Center, Inc.
phone: 800-778-2860
e-mail: clinicaltrialregistry@tpna.com



Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00787254     History of Changes
Other Study ID Numbers: AG-1749-CCT-352
070495 ( Registry Identifier: JapicCTI )
U1111-1114-2071 ( Registry Identifier: WHO )
R100126 ( Registry Identifier: JapicCTI )
First Submitted: November 6, 2008
First Posted: November 7, 2008
Results First Submitted: February 3, 2011
Results First Posted: May 10, 2011
Last Update Posted: February 3, 2012